Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

• Alexander N Shoushtari,
• Katherine S Panageas,
• Jedd D Wolchok,
• Paul B Chapman,
• Margaret Callahan,
• Allison Betof Warner,
• Vetri Sudar Jayaprakasam

Affiliations

Alexander N Shoushtari

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Katherine S Panageas

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Jedd D Wolchok

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Paul B Chapman

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Margaret Callahan

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Allison Betof Warner

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Vetri Sudar Jayaprakasam

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA